A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes
Condition: Atrial Fibrillation Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Warfarin Sponsors: Bayer; Janssen Research and Development LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Atrial Fibrillation | Coumadin | Diabetes | Endocrinology | Learning | Research | Study | Universities & Medical Training | Warfarin